ClinicalTrials.gg
RecruitingNCT07497399TAG-MSUpdated Nov 10, 2026

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

A Phase 2 interventional study of NLY01 and Placebo in Multiple Sclerosis, sponsored by Johns Hopkins University. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 10, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Multiple Sclerosis by Johns Hopkins University — 4 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Johns Hopkins University.

Planned enrollment
3rd of 18
120 · median 48
Started
2026
with 1 other
Phase 2
4 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Multiple Sclerosis by Johns Hopkins University, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 20th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 20 studies in Multiple Sclerosis by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Multiple Sclerosis by Johns Hopkins University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
  • Aged 18-60 years
  • ≥27.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • No GLP-1RA or GIP/GLP-1 RA in past year; no known to medication class
  • No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis
  • No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2
  • No chronic kidney disease (estimated ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse
  • No concerns about candidacy of individual on part of person's neurologist or study team clinicians
  • Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable (contraception requirements as discussed below)***

    • currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) \& meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of \<1%/year, or two methods of lesser effectiveness:

Contraceptive methods with a failure rate of \< 1% per year includes the following:

  • Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
  • Complete abstinence from sexual encounters with a person who has testes

Those who do not wish to use one of the above methods of contraception must use two methods. Options include:

  • Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.
  • Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:

    • A condom with or without spermicide
    • A cap, diaphragm, or sponge with or without spermicide

      • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    NLY01 (Study Drug)

    5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage.

    Drug: NLY01

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in normalized (for head size) brain parenchymal volume (nBPV)

    Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation

    Time frame: Baseline, week 48, and week 96

Secondary outcomes

  1. Change in normalized gray matter volume (mL)

    Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks).

    Time frame: Baseline, week 48, and week 96

  2. Change in thalamic volume (mL)

    Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation.

    Time frame: Baseline, week 48, and week 96

  3. Change in cortical thickness (mm)

    Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation.

    Time frame: Baseline, week 48, and week 96

  4. Change in retinal nerve fiber layer thickness

    Measured in μm, from randomization to end of treatment (approximately 96 weeks),

    Time frame: Baseline, week 48, and week 96

  5. Change in ganglion cell/inner plexiform thickness

    Measured in μm, from randomization to end of treatment (approximately 96 weeks),

    Time frame: Baseline, week 48, and week 96

  6. Disability progression as assessed by the Expanded Disability Status Scale (EDSS)

    Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression

    Time frame: Approximately every 24 weeks, up to 96 weeks

  7. Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)

    The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  8. Disability progression as assessed by the Expanded Disability Status Scale-Plus

    The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is \>5.5).

    Time frame: Approximately every 24 weeks, up to 96 weeks

  9. Patient-reported disability progression as assessed by the Patient-Determined Disease Steps

    Patient-Determined Disease Steps score range 0-8; higher is worse progression

    Time frame: Approximately every 24 weeks, up to 96 weeks

  10. Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  11. Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  12. Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  13. Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  14. Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  15. Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  16. Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  17. Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  18. Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  19. Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale

    Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

    Time frame: Approximately every 24 weeks, up to 96 weeks

  20. Adverse events

    Proportion of individuals in each arm experiencing adverse events

    Time frame: From randomization to week 96

  21. Serious adverse events

    Proportion of individuals in each arm experiencing serious adverse events

    Time frame: From randomization to week 96

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available 6 months after publication and remain accessible for 12-24 months.

Access criteria: Qualified researchers who have completed and signed approvals for data sharing.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2030, 45 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 45 months is close to that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 27, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. University of Kansas Medical Center is now Recruiting
Show site
  • University of Kansas Medical Center · Kansas City, United States
across 2 updates, Nov 5, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    University of Kansas Medical Center is now Recruiting
  2. Nov 5, 2026
    1 site added
    Show site
    • University of Kansas Medical Center · Kansas City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07497399
Collaborators
National Multiple Sclerosis Society, Race to Erase MS
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 28, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Study Manager
Contact
mvieira4@jh.edu
667-306-8153
Ellen M Mowry, MD, MCR
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegsebrenatide

Start the discussion